Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen
Study Overview
Brief Summary
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy
Exclusion Criteria
- •Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent
Arms & Interventions
Tocilizumab
Intervention: Tocilizumab (Drug)
Remdesivir
Intervention: Tocilizumab (Drug)
Standard Treatment
Intervention: Tocilizumab (Drug)
Outcomes
Primary Outcomes
Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen
Time Frame: 7 days
Secondary Outcomes
- Hospital stay(15 days)
- Viral load(7-15 days)
- Oxygen demand(7-15 days)
Investigators
Dr Muhammad Mansoor Hafeez
Doctor
University of Lahore